|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Tempero MA, Arnoletti JP, Behrman SW, et
al: Pancreatic Adenocarcinoma, version 2.2012: featured updates to
the NCCN Guidelines. J Natl Compr Cancer Netw. 10:703–713.
2012.PubMed/NCBI
|
|
3
|
Cunningham D, Chau I, Stocken DD, et al:
Phase III randomized comparison of gemcitabine versus gemcitabine
plus capecitabine in patients with advanced pancreatic cancer. J
Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raguz S and Yague E: Resistance to
chemotherapy: new treatments and novel insights into an old
problem. Br J Cancer. 99:387–391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arlt A, Muerkoster SS and Schafer H:
Targeting apoptosis pathways in pancreatic cancer. Cancer Lett.
November 13–2010. View Article : Google Scholar
|
|
7
|
Wan F and Lenardo MJ: The nuclear
signaling of NF-kappaB: current knowledge, new insights, and future
perspectives. Cell Res. 20:24–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sebens S, Arlt A and Schafer H: NF-kappaB
as a molecular target in the therapy of pancreatic carcinoma.
Recent Results Cancer Res. 177:151–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanarek N, London N, Schueler-Furman O and
Ben-Neriah Y: Ubiquitination and degradation of the inhibitors of
NF-kappaB. Cold Spring Harb Perspect Biol. 2:a0001662010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Biswas DK, Martin KJ, McAlister C, et al:
Apoptosis caused by chemotherapeutic inhibition of nuclear
factor-kappaB activation. Cancer Res. 63:290–295. 2003.PubMed/NCBI
|
|
11
|
Gyrd-Hansen M and Meier P: IAPs: from
caspase inhibitors to modulators of NF-kappaB, inflammation and
cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eckelman BP, Salvesen GS and Scott FL:
Human inhibitor of apoptosis proteins: why XIAP is the black sheep
of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chandler NM, Canete JJ and Callery MP:
Increased expression of NF-kappa B subunits in human pancreatic
cancer cells. J Surg Res. 118:9–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weichert W, Boehm M, Gekeler V, et al:
High expression of RelA/p65 is associated with activation of
nuclear factor-kappaB-dependent signaling in pancreatic cancer and
marks a patient population with poor prognosis. Br J Cancer.
97:523–530. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arlt A, Gehrz A, Muerkoster S, et al: Role
of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma
cell lines against gemcitabine-induced cell death. Oncogene.
22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong R, Sun B, Jiang H, et al:
Downregulation of nuclear factor-kappaB p65 subunit by small
interfering RNA synergizes with gemcitabine to inhibit the growth
of pancreatic cancer. Cancer Lett. 291:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pan X, Arumugam T, Yamamoto T, et al:
Nuclear factor-kappaB p65/relA silencing induces apoptosis and
increases gemcitabine effectiveness in a subset of pancreatic
cancer cells. Clin Cancer Res. 14:8143–8151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kashkar H: X-linked inhibitor of
apoptosis: a chemoresistance factor or a hollow promise. Clin
Cancer Res. 16:4496–4502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shrikhande SV, Kleeff J, Kayed H, et al:
Silencing of X-linked inhibitor of apoptosis (XIAP) decreases
gemcitabine resistance of pancreatic cancer cells. Anticancer Res.
26:3265–3273. 2006.PubMed/NCBI
|
|
20
|
Lopes RB, Gangeswaran R, McNeish IA, Wang
Y and Lemoine NR: Expression of the IAP protein family is
dysregulated in pancreatic cancer cells and is important for
resistance to chemotherapy. Int J Cancer. 120:2344–2352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Jian Z, Xia K, et al: XIAP is
related to the chemoresistance and inhibited its expression by RNA
interference sensitize pancreatic carcinoma cells to
chemotherapeutics. Pancreas. 32:288–296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan Y, Dutta J, Gupta N, Fan G and Gelinas
C: Regulation of programmed cell death by NF-kappaB and its role in
tumorigenesis and therapy. Adv Exp Med Biol. 615:223–250. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liptay S, Weber CK, Ludwig L, Wagner M,
Adler G and Schmid RM: Mitogenic and antiapoptotic role of
constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J
Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trauzold A, Schmiedel S, Roder C, et al:
Multiple and synergistic deregulations of apoptosis-controlling
genes in pancreatic carcinoma cells. Br J Cancer. 89:1714–1721.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oh JH, Cho MC, Kim JH, et al: IL-32γ
inhibits cancer cell growth through inactivation of NF-κB and STAT3
signals. Oncogene. 30:3345–3359. 2011.
|
|
26
|
Aggarwal S, Ichikawa H, Takada Y, Sandur
SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane)
down-regulates expression of cell proliferation and antiapoptotic
and metastatic gene products through suppression of IkappaBalpha
kinase and Akt activation. Mol Pharmacol. 69:195–206.
2006.PubMed/NCBI
|
|
27
|
Manna SK, Aggarwal RS, Sethi G, Aggarwal
BB and Ramesh GT: Morin (3,5,7,2′,4′-Pentahydroxyflavone) abolishes
nuclear factor-kappaB activation induced by various carcinogens and
inflammatory stimuli, leading to suppression of nuclear
factor-kappaB-regulated gene expression and up-regulation of
apoptosis. Clin Cancer Res. 13:2290–2297. 2007.
|
|
28
|
Moon DO, Kim MO, Lee JD and Kim GY:
Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene
expression in human leukemia U937 cells. Cancer Lett. 264:192–200.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bilim V, Yuuki K, Itoi T, et al: Double
inhibition of XIAP and Bcl-2 axis is beneficial for retrieving
sensitivity of renal cell cancer to apoptosis. Br J Cancer.
98:941–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kunze D, Wuttig D, Fuessel S, et al:
Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2,
BCL-X(L)) in bladder cancer cells. Anticancer Res. 28:2259–2263.
2008.PubMed/NCBI
|
|
32
|
Ruckert F, Samm N, Lehner AK, Saeger HD,
Grutzmann R and Pilarsky C: Simultaneous gene silencing of Bcl-2,
XIAP and Survivin re-sensitizes pancreatic cancer cells towards
apoptosis. BMC Cancer. 10:3792010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liston P, Fong WG and Korneluk RG: The
inhibitors of apoptosis: there is more to life than Bcl2. Oncogene.
22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seeger JM, Brinkmann K, Yazdanpanah B, et
al: Elevated XIAP expression alone does not confer chemoresistance.
Br J Cancer. 102:1717–1723. 2010. View Article : Google Scholar : PubMed/NCBI
|
